Jonathan Hopper - Feb 6, 2023 Form 4 Insider Report for Vericel Corp (VCEL)

Role
Chief Medical Officer
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Stock symbol
VCEL
Transactions as of
Feb 6, 2023
Transactions value $
-$9,486
Form type
4
Date filed
2/8/2023, 03:05 PM
Previous filing
Mar 3, 2022
Next filing
Feb 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VCEL Common Stock Options Exercise $0 +650 +1.32% $0.00 49.7K Feb 6, 2023 Direct F1, F2
transaction VCEL Common Stock Tax liability -$9.49K -310 -0.62% $30.60 49.4K Feb 6, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VCEL Restricted Stock Unit Options Exercise -650 -100% 0 Feb 6, 2023 Common Stock 650 Direct F1, F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on February 6, 2019.
F2 These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F3 These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of RSUs.
F4 Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation.
F5 No expiration date for this type of award.
F6 The Fair Market Value of the vested derivative securities is $30.60 per share.